Skip to main content

ICICI Lombard, EID Parry, and ICICI Prudential can give up to 12% return in the short term

On the technical front, now 13,000 should act as strong resistance for Nifty while 29,500 would be an immediate hurdle for Bank Nifty.

ICICI Lombard General Insurance Company | LTP: Rs 1,317.55 | Target price: Rs 1,480 | Stop loss: Rs 1,230 | Upside: 12%

For the last three months, the stock has been consistently moving lower in a downward sloping channel with the formation of the lower high and lower bottom pattern.

However, this week, the stock has once again moved back above its key resistance levels of Rs 1,320 with a breakout above the falling trendline of the sloping channel.

The breakout can be seen with rising volumes and positive divergences on secondary oscillators.

The stock is holding well above its long-term moving averages on daily and weekly intervals.

EID Parry India | LTP: Rs 301 | Target price: Rs 337 | Stop loss: Rs 273 | Upside: 12%

For the last nearly seven weeks, the stock has been consolidating in a broader range of Rs 265-295 along with consistent buying around support levels.

On the daily and weekly charts, the stock is holding well above its short and long-term moving averages.



At the current juncture, the stock has formed an inverted head and shoulder pattern on the daily charts and managed to give a breakout above the neckline of the pattern formation.

ICICI Prudential Life Insurance Company | LTP: Rs 449.70 | Target price: Rs 494 | Stop loss: Rs 415 | Upside: 10%

After testing Rs 487 levels in August, the stock was seen continuously trading lower in a downward sloping channel with the formation of the lower high and lower bottom pattern.

However, it managed to take support at its 200-day exponential moving average on the weekly charts and bounced back after forming a double bottom pattern at Rs 400 levels on the daily charts.

This week, the stock has once again moved back above its key resistance level of Rs 440 with the breakout above the falling trendline of the sloping channel.

The positive divergence on secondary oscillators with a breakout suggests further upside in the prices.

Disclaimer:- Investments in securities market are subject to risk. Consult your financial advisor before taking any of above calls.

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more